Trade Hoth Therapeutics - HOTH CFD

Trading Conditions

• Spread: 0.0622
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.01
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 1.1439
• Open: 1.1339
• 1-Year Change: -42.26%
• Day's Range: 1.1339 - 1.1639

Hoth Therapeutics Company profile

About Hoth Therapeutics Inc

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapy for dermatological disorders including atopic dermatitis (eczema), chronic wounds, psoriasis, asthma and acne. The Company is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer, a treatment for asthma and allergies using inhalational administration, a topical treatment for patients with lupus, a treatment for mast-cell derived cancers and anaphylaxis, and a treatment for lung diseases resulting from bacterial infections. The Company's product pipelines include HT-001, HT-003, HT-004 and others. HT-001 is used to treat patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor (EGFR) inhibitor therapy. It is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Hoth Therapeutics Inc revenues was not reported. Net loss increased 68% to $10.8M. Higher net loss reflects Research and development increase from $2.1M to $5.4M (expense), Compensation and related expenses (inclu increase from $1.2M to $2.5M (expense), Other general and administrative expense increase of 68% to $606K (expense).